14th World Conference on Lung Cancer Press program

PRESS BRIEFINGS:

 

Monday, July 4, 2011

10:00-11:00

CT Screening for Lung Cancer

Moderator: David Gandara, UC Davis Cancer Center, U.S.A.

Panelists:

John Field, University of Liverpool Cancer Research Centre, U.K.

David Baldwin, Nottingham Lung Cancer Centre, U.K.

Denise Aberle, UCLA, U.S.A.

Jesper Pedersen, Copenhagen University Hospital, Denmark

James Mulshine, Rush University, U.S.A.

Roy Herbst, Yale School of Medicine, U.S.A.

Richard Gralla, North Shore-LIJ Health System, U.S.A.

 

 

Tuesday, July 5, 2011

10:00-11:00

Biomarkers and Personalized Therapy

Moderator: Roy Herbst, Yale School of Medicine, U.S.A.

Lung tumors in never smokers show greater genomic instability than those in smokers 

                         Kelsie Thu, BC Cancer Agency Research Center, Canada

ALK rearrangement found in nearly 10% of patients in Lung Cancer Mutation Consortium

                         Marileila Varella Garcia, University of Colorado School of Medicine, U.S.A.

                         Bruce Johnson, Harvard Medical School, U.S.A.

EURTAC Phase III study: Erlotinib nearly doubles progression-free survival v. chemotherapy 

                         Radj Gervais, Centre Francois Baclesse, France

High EGFR expression a predictor for improved survival with cetuximab plus chemotherapy 

                         Robert Pirker, University of Vienna Medical School, Austria

PET scan with [11C] erlotinib may provide non-invasive method to identify TKI-responsive lung tumors 

                         Idris Bahce, VU University Medical Center, The Netherlands

 

Wednesday, July 6, 2011

10:00-11:00

Improvements in Care

Moderator: Paul van Schil, Antwerp University Hospital, Belgium    

Increased investment in thoracic surgical expertise increased UK lung cancer resection rate

                         David Waller, Glenfield Hospital, Leicester, U.K.

Elderly Dutch lung patients' survival improved by new treatment options between 2003-2009 

                         Suresh Senan, VU University Medical Center, The Netherlands

Women, elderly and minorities poorly represented in lung cancer drug trial data submitted to U.S. FDA                          

                         Shakun Malik, VU University Medical Center, The Netherlands

Canada's Cancer Risk Management (CRM) model is an important new health tool for policymakers 

                          William Evans, Juravinski Cancer Centre, Canada

 

Thursday, July 7, 2011

10:00-11:00

Improvements in Practice

Moderator: Richard Gralla, North Shore-LIJ Health System, U.S.A.

Amrubicin improved response rate and progression-free survival vs. topotecan in Phase III trial

                             Joachim von Pawel, Asklepios Hospital Munich-Gauting, Germany

TEMLA shows higher diagnostic yield than EBUS or EUS in largest reported series to date

                              Marcin Zielinski, Specialist Pulmonary Hospital, Poland

Endosonography followed by surgical staging improves quality of life, according to ASTER study

                              Robert Rintoul, Papworth Hospital, U.K.

Cancer patients with blood clots gain no benefit from addition of a vena cava filter to treatment with fondaparinux

                              Myra Barginear, Hofstra North Shore-LIJ School of Medicine, U.S.A.

 

 

OTHER WCLC PRESS RELEASES:

 

IASLC welcomes publication of CT screening results from National Lung Screening Trial (June 29, 2011)

Five advocacy organizations win travel awards to attend WCLC in Amsterdam (June 1, 2011)

Press program announced for 2011 World Conference on Lung Cancer (May 16, 2011)

IASLC to help advocacy organizations attend 14th WCLC in Amsterdam (March 4, 2011)

Online registration opens for 14th World Conference on Lung Cancer in Amsterdam (Jan. 4, 2011)